Physician profile
Jamison Stan Rees
NPI 1982231312
$3,497.92
in general payments reported to CMS, 2019-2025
28 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $167 · 2023: $498 · 2024: $1,120 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $768.79 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.85 | 2021-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $339.33 | 2021-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $325.12 | 2021-2022 | |
| Amgen INC. | $262.98 | 2021-2025 | Evenity, Prolia |
| Indivior INC. | $197.24 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.83 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $161.36 | 2021 | |
| Pfizer INC. | $126.16 | 2024-2025 | |
| Kaleo, INC. | $108.86 | 2021-2022 | |
| Axsome Therapeutics, INC. | $84.71 | 2023-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $72.19 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $61.62 | 2023-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $60.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.22 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $47.42 | 2022-2023 | Xembify |
| Phathom Pharmaceuticals, INC. | $44.82 | 2024 | Voquezna |
| Exact Sciences Corporation | $42.67 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $33.32 | 2021 | |
| Lilly USA, LLC | $30.26 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Inspire Medical Systems, INC. | $25.40 | 2025 | Inspire |
| Adma Biomanufacturing LLC | $21.02 | 2022 | |
| Astellas Pharma US INC | $20.28 | 2024 | Veozah |
| Optinose US, INC. | $18.60 | 2021 | |
| Shield Therapeutics INC | $17.01 | 2024 | |
| Organon LLC | $13.81 | 2024 | |
| Azurity Pharmaceuticals, INC. | $13.77 | 2025 | Alvesco |
| Lucid Diagnostics INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.